Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 5/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | SLC9A3 | P48764 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24759892 | 0.89 | TSHR (0.43) | L3MBTL1TSHRRECQLSLC9A3MEN1 | |
| SCHEMBL21291271 | 0.88 | TSHR (0.48) | L3MBTL1TSHRSLC9A3ALDH1A1TAAR1 | |
| SCHEMBL24588486 | 0.88 | L3MBTL1 (0.45) | L3MBTL1TSHRSLC9A3 | |
| SCHEMBL24840970 | 0.88 | L3MBTL1 (0.38) | L3MBTL1TSHRSLC9A3 | |
| SCHEMBL25344467 | 0.87 | L3MBTL1 (0.41) | L3MBTL1TSHRRECQLSLC9A3 | |
| SCHEMBL21290595 | 0.86 | GAA (0.36) | L3MBTL1TSHRSLC9A3 | |
| SCHEMBL24759042 | 0.86 | L3MBTL1 (0.41) | L3MBTL1TSHRSLC9A3 | |
| SCHEMBL21290649 | 0.85 | L3MBTL1 (0.43) | L3MBTL1TSHRSLC9A3 | |
| SCHEMBL25344641 | 0.85 | TSHR (0.47) | L3MBTL1TSHRSLC9A3 | |
| SCHEMBL25344833 | 0.84 | L3MBTL1 (0.41) | L3MBTL1SLC9A3ALDH1A1TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220402947-A1 | Trialkyne Linking Agents and Methods of Use | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2022-12-22 | — | — | US | disclosed |
| WO-2019161213-A1 | TRIALKYNE LINKING AGENTS AND METHODS OF USE | Arrowhead Pharmaceuticals, Inc. (US) | 2019-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220402947-A1 | Trialkyne Linking Agents and Methods of Use | DCLRE1A, DTYMK, RTCB | L3MBTL1 570/4885TSHR 3215/4885RECQL 608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.